Revolutionizing protein modification: a new frontier in cancer research
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-May-2025 11:08 ET (1-May-2025 15:08 GMT/UTC)
Scientists have long struggled to target proteins that lack defined structure and are involved in cancer, neurodegenerative disorders like Parkinson’s disease, and other serious illnesses. Now, a new study from Scripps Research demonstrates a proof of concept for a new strategy: engineering proteases—enzymes that cut proteins at specific sites—to selectively degrade these elusive targets with high precision in the proteome of human cells.
Initiative aims to transform Guyana’s public health system by 2030 with world-class healthcare services accessible to all citizens, especially vulnerable communities
Researchers from the University of Colorado Cancer Center have solved a cellular mystery that may lead to better therapies for colorectal and other types of cancer.
Peter Dempsey, PhD, professor of pediatrics–developmental biology in the CU School of Medicine, and Justin Brumbaugh, PhD, assistant professor of molecular, cellular, and developmental biology at CU Boulder, recently published a paper in the journal Nature Cell Biology showing the importance of the H3K36 methylation process in regulating plasticity and regeneration in intestinal cells.
Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many proteins group together in what are called protein complexes to carry out biological functions. The traditional method of generating antibodies by immunizing animals struggles to make antibodies related to these protein complexes.
Scientists at Sanford Burnham Prebys and Eli Lilly and Company published findings March 5, 2025, in the Journal of Immunology demonstrating that fusing protein complexes together adds stability during immunization and enables antibody generation.New Haven, Conn. — Yale scientists have discovered a promising way to trigger immune responses against certain tumors, using a lupus-related antibody that can slip, undetected, into “cold” tumors and flip on an immune response that has been turned off by cancer. The research, published in Science Signaling on March 25, offers new findings that could help improve therapies for glioblastoma and other aggressive cancers that are difficult to treat.
New research offers unprecedented insight into how an enigmatic enzyme, known as CDK7, drives the cell cycle and cell proliferation.
A patient’s race and location may influence diagnostic testing for prostate tumors.